- |||||||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Omvoh (mirikizumab-mrkz) / Eli Lilly, Tremfya (guselkumab) / J&J
Review, Journal: New Interleukin-23 Antagonists' Use in Crohn's Disease. (Pubmed Central) - Apr 27, 2025 Selective new IL-23 inhibitors represent a targeted and effective therapeutic class for moderately to severely active CD, offering high clinical and endoscopic remission rates, and favorable safety outcomes. Continued research, particularly on long-term efficacy and the selection of patients based on inflammatory biomarkers, will help optimize their role in personalized treatment strategies for refractory CD.
- |||||||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Stelara (ustekinumab) / J&J
IL-23-ACTIVATED CELLS AS RESPONSE BIOMARKERS FOR IL-23 ANTAGONISTS IN CROHN'S DISEASE (Halls C-E, Lower Level - SDCC) - Mar 8, 2025 - Abstract #DDW2025DDW_4303; CyTOF of CD patients' cells revealed previously unknown molecular signatures, especially augmented TNF-a production in multiple IL-23-activated cells, in prediction of non-response to risankizumab. Those findings identified a novel mechanism of anti-IL-23 resistance, may help identify response biomarkers for IL-23 antagonists and provide a rationale for anti-IL-23/anti-TNF combination therapy in selected patients with refractory CD.
- |||||||||| Ilumya (tildrakizumab-asmn) / Sun Pharma, Almirall
The Clinical and Molecular Response of Pyoderma Gangrenosum to Interleukin 23 Blockade: Result from a proof-of-concept open-label clinical trial () - Feb 21, 2025 - Abstract #AAD2025AAD_2362; We present the results of a proof-of-concept open label clinical trial of IL-23p19 antagonism with Tildrakizumab in Pyoderma Gangrenosum...Differential clinical and molecular response was seen when peristomal and pretibial PG lesions were compared, suggesting that IL-23 antagonism is less effective in the setting of peristomal disease. This novel data provides insights into the clinical relevance of alterations in molecular markers in pyoderma gangrenosum and the potential for the identification of clinically relevant biomarkers of disease activity.
- |||||||||| Review, Journal, Metastases: Modern Advanced Therapies for Inflammatory Bowel Diseases: Practical Considerations and Positioning. (Pubmed Central) - Feb 13, 2025
In this review, we discuss practical use of these newer advanced therapies focusing on real-world effectiveness and safety data, dosing and monitoring considerations, as well as special situations for their use such as pregnancy, co-morbid immune-mediated disease, use in hospitalized patients with acute severe UC, and in the perioperative setting. We also propose our approach to positioning these therapies in clinical practice, relying on careful integration of the medication's comparative effectiveness and safety in the context of an individual patient's risk of disease- and treatment-related complications and preferences.
- |||||||||| Journal: Unravelling the complex pathogenesis of hidradenitis suppurativa. (Pubmed Central) - Feb 3, 2025
The cutaneous and gut microbiomes play significant roles in the activation of innate immunity, although conflicting data exist as to their central or peripheral role in disease pathogenesis. Overall, our understanding of disease pathogenesis in HS is moving toward a more nuanced, complex paradigm in which patient heterogeneity in presentation and immunological characteristics are moving closer to the identification of therapeutic biomarkers to guide therapeutic modalities in the management of this burdensome condition.
- |||||||||| Rinvoq (upadacitinib) / AbbVie
Safety of tofacitinib and upadacitinib compared to other advanced therapies in ulcerative colitis: a large real-world comparison. (Poster exhibition) - Jan 22, 2025 - Abstract #ECCOIBD2025ECCO_IBD_2106; We compared each JAKi with TNF, IL-23 antagonists, and vedolizumab, and within the class by survival analyses and log-rank test...Results Only tofacitinib and upadacitinib were included, as data on filgotinib were not available...Conclusion Anti-JAK show a similar safety profile than all the other drug classes used in UC. Herpes zoster infection/reactivation remains the only adverse event of note for both JAKi.
- |||||||||| Journal: Breakthrough Psoriasis in Patients Receiving Biologicals. (Pubmed Central) - Jan 12, 2025
Herpes zoster infection/reactivation remains the only adverse event of note for both JAKi. Breakthrough psoriasis is an exceptional event among patients with stabilized psoriasis using biologicals, either triggered by the K
- |||||||||| Tremfya (guselkumab) / J&J
Characteristics of Response to IL-23 inhibition: Post-Hoc Analysis of the Phase 2 Nova Trial (Waller Salons CD) - Oct 23, 2024 - Abstract #SHSA2024SHSA_47; Discussion Mechanistic data suggests that sex hormones play a significant role in monocyte polarization and development, leading to the hypothesis that men, and men with lower BMI, may have greater clinical response to IL-23 antagonism. The results from this post-hoc reanalysis identify that men have a greater clinical response to Guselkumab than women, reaching significance in outcomes including HiSCR-75 and AN count.
- |||||||||| Review, Journal: Targeted therapies for uveitis in spondyloarthritis: a narrative review. (Pubmed Central) - Oct 2, 2024
Mixed results have been demonstrated with interleukin-17 antagonists (secukinumab) and interleukin-12/interleukin-23 antagonists (ustekinumab) in cases of failure of TNFis...Although SpA-related uveitis is typically managed with conventional local and/or systemic treatments, these biological/targeted therapies may provide avenues to control both the underlying SpA and uveitis manifestations. Thus, a close collaboration between patients, rheumatologists, internists, and ophthalmologists is needed to optimally manage ocular inflammation in SpA.
- |||||||||| Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim
Dose Intensification of Risankizumab for Crohn's Disease: Access and Outcomes (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_4894; 14 (47%) prescriptions were initially approved by insurance and 16 (53%) were denied and then appealed. Ten (63%) appeals were ultimately successful after a median of 23 days (IQR 15-43 days).
- |||||||||| Stelara (ustekinumab) / J&J, Entyvio (vedolizumab) / Takeda
Comparing Ustekinumab and Vedolizumab in Inflammatory Bowel Disease Patients Exposed to Anti-TNF Agents: A Propensity-Matched, Retrospective Cohort Study (Exhibit Hall E) - Aug 20, 2024 - Abstract #ACG2024ACG_1358; The median follow-up was 730 days for each cohort. The UST cohort showed significantly reduced risks of all-cause mortality (HR: 0.58, 95% CI: 0.40-0.84), fistula formation (HR: 0.695, 95% CI: 0.606-0.797), abscess formation (HR: 0.763, 95% CI: 0.712-0.817), and steroid use (HR: 0.88, 95% CI: 0.835-0.928) compared to the VDZ cohort.
- |||||||||| Rinvoq (upadacitinib) / AbbVie
Journal, Surgery: Biologics, small molecule therapies and surgery in small bowel Crohn's disease. (Pubmed Central) - Apr 4, 2024 Current therapies for induction and maintenance of remission in moderate to severe Crohn's disease include several classes of monoclonal antibodies and a Janus Kinase inhibitor, upadacitinib. While small bowel Crohn's disease is generally less responsive to treatment, anti-TNFs are still preferred as first line therapy, and the option of early ileocecal resection in early limited ileal disease is gaining interest.
- |||||||||| EFFICACY AND SAFETY OF ADVANCED MEDICAL TREATMENTS FOR INDUCTION OF REMISSION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (Hall A) - Mar 14, 2024 - Abstract #DDW2024DDW_4909;
There was moderate certainty of evidence for combination of ADA and azathioprine (AZA) (RR 3...ConclusionOn network meta-analysis combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have examples of similarly important effect sizes but are currently limited due to the imprecision of the limited evidence base at present and future research should target these therapies in study
- |||||||||| Immunomodulator and advanced therapies for Induction of clinical remission and response in Crohn (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1637;
There was moderate certainty of evidence for combination of ADA and azathioprine (AZA) (RR 3.1, 95%CI [2.0-4.8]; risk difference [RD]: 40.1%), IFX+AZA (RR 2.5, 95%CI [1.7-3.8]; RD: 28.9%), ADA (RR 2.5, 95%CI [1.8-3.5]; RD:28.5%), and UST (RR 2.0 95%CI, [1.6-2.5]; RD: 19.2%) in induction of clinical remission compared to placebo...Conclusion On network meta-analysis, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have examples of similarly important effect sizes, but are currently limited due to the imprecision of the limited evidence base at present and future research should target these therapies in study.
- |||||||||| Review, Journal: Pathological mechanism and targeted drugs of ulcerative colitis: A review. (Pubmed Central) - Sep 20, 2023
monoclonal antibodies, integrin antagonists, IL-12/IL-23 antagonists, novel UC-targeted drugs such as JAK inhibitors and SIP receptor agonists. We believe that rational selection of targeted drugs and formulation of the best dosing strategy under the comprehensive consideration of clinical evaluation is the best way to treat UC.
- |||||||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation (e-Poster Hall) - Aug 30, 2023 - Abstract #EADV2023EADV_2753; The shutdown of the inflammatory setting and the partial silencing of the memory side could then represent a pathophysiological suggestion of why the lack of response to an anti-IL-23 mAb does not affect the efficacy of a drug of the same class. Our preliminary data showed that switching to risankizumab among IL-23 blockers experienced patients could be a valid clinical choice able to lead to satisfactory results in terms of achieving PASI90 and PASI100 (Figure 1).
- |||||||||| Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim
Buy Two, Get One: De Novo IBD Onset Following Kidney Transplant and Immunosuppression (Exhibit Hall) - Jul 29, 2023 - Abstract #ACG2023ACG_2739; Our preliminary data showed that switching to risankizumab among IL-23 blockers experienced patients could be a valid clinical choice able to lead to satisfactory results in terms of achieving PASI90 and PASI100 (Figure 1). Other post-transplant gastrointestinal complications like cytomegalovirus (CMV) colitis or mycophenolate mofetil (MMF) colitis are more likely; therefore, de novo IBD is a diagnosis of exclusion...His maintenance immunosuppression included tacrolimus, MMF and prednisone...Paradoxically, this case study presents de novo IBD that responds well to additional immunosuppression of risankizumab, an IL-23 antagonist for Crohn
- |||||||||| Efficacy of anti-IL17 treatment in patients with moderate-severe plaque psoriasis who had failed IL-23 inhibitors () - Jul 3, 2023 - Abstract #WCD2023WCD_6789;
Other post-transplant gastrointestinal complications like cytomegalovirus (CMV) colitis or mycophenolate mofetil (MMF) colitis are more likely; therefore, de novo IBD is a diagnosis of exclusion...His maintenance immunosuppression included tacrolimus, MMF and prednisone...Paradoxically, this case study presents de novo IBD that responds well to additional immunosuppression of risankizumab, an IL-23 antagonist for Crohn First two patients prior to switch were receiving Risankizumab while last three were receiving Guselkumab for 7, 10, 5, 5 and 9 months respectively...First three patients switched to Brodalumab while later two to ixekizumab...Therefore we conclude that when patients fail to respond to an IL-23 antagonist, the IL-23/IL-17 axis is not
|